Mirum Pharmaceuticals Company Leadership
| MIRM Stock | USD 43.48 0.21 0.48% |
Mirum Pharmaceuticals employs about 311 people. The company is managed by 11 executives with a total tenure of roughly 726 years, averaging almost 66.0 years of service per executive, having 28.27 employees per reported executive. Analysis of Mirum Pharmaceuticals' management performance can provide insight into the firm performance.
Mirum |
Mirum Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.091) % which means that it has lost $0.091 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3984) %, meaning that it created substantial loss on money invested by shareholders. Mirum Pharmaceuticals' management efficiency ratios could be used to measure how well Mirum Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Mirum Pharmaceuticals Workforce Comparison
Mirum Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 4,060. Mirum Pharmaceuticals holds roughly 311 in number of employees claiming about 8% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.33) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.14) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.14. Mirum Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mirum Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mirum Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Mirum Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mirum Pharmaceuticals Notable Stakeholders
A Mirum Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Mirum Pharmaceuticals often face trade-offs trying to please all of them. Mirum Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Mirum Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Christopher Peetz | CEO Director | Profile | |
| Peter MBA | Chief Officer | Profile | |
| Eric MBA | Chief Officer | Profile | |
| Ian Clements | Chief Officer | Profile | |
| Paul Ross | Chief Officer | Profile | |
| MSC MBA | Chief Officer | Profile | |
| Pamela Vig | Chief Research | Profile | |
| Erin Campany | Senior Resources | Profile | |
| Vinita Kumar | Senior Quality | Profile | |
| Andrew McKibben | Vice Finance | Profile | |
| JeanLuc Girardet | Senior Operations | Profile |
About Mirum Pharmaceuticals Management Performance
The success or failure of an entity such as Mirum Pharmaceuticals often depends on how effective the management is. Mirum Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Mirum management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Mirum management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California. Mirum Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 171 people.
Mirum Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Mirum Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Mirum Pharmaceuticals within its industry.Mirum Pharmaceuticals Manpower Efficiency
Return on Mirum Pharmaceuticals Manpower
| Revenue Per Employee | 599.3K | |
| Revenue Per Executive | 16.9M | |
| Net Loss Per Employee | 525.5K | |
| Net Loss Per Executive | 14.9M | |
| Working Capital Per Employee | 966.2K | |
| Working Capital Per Executive | 27.3M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.